Eva Cristobal
Primary Care · Glendora, CANPI 1184146631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 39.7% of the total. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$818
- Madrigal Pharmaceuticals$587
- Johnson & Johnson$363
- Ardelyx, Inc.$307
- Bristol Myers Squibb$223
- plus $1K from 19 others
What the payments were for
- Food & beverage$6,072100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 134 | $2,421 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $818 |
| Madrigal Pharmaceuticals | 24 | $587 |
| Johnson & Johnson | 13 | $363 |
| Ardelyx, Inc. | 19 | $307 |
| Bristol Myers Squibb | 21 | $223 |
| Gilead | 12 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $208 |
| Intercept Pharmaceuticals, Inc. | 6 | $136 |
| Redhill Biopharma Inc. | 7 | $128 |
| Novo Nordisk | 1 | $124 |
| Fresenius Kabi USA, LLC | 3 | $97 |
| Ironwood Pharmaceuticals, Inc | 6 | $95 |
| QOL Medical, LLC | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Celltrion USA Inc. | 2 | $42 |
| Exact Sciences | 2 | $36 |
| Phadia US Inc. | 2 | $34 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Philips North America LLC | 1 | $29 |
| Sarepta Therapeutics, Inc. | 1 | $23 |
| Evoke Pharma, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Apollo Endosurgery US Inc | 1 | $14 |
How this compares
$6,099 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 32 | $27,814 |
| CreonLipase/Protease/Amylase | 19 | $26,461 |
| VemlidyTenofovir Alafenamide | 11 | $17,995 |
| TrulancePlecanatide | 15 | $7,679 |
| Dexlansoprazole DrDexlansoprazole | 27 | $6,028 |
| Cholestyramine LightCholestyramine | 53 | $5,825 |
| Mesalamine | 26 | $4,909 |
| Famotidine | 168 | $3,090 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 177 | $2,765 |
| CholestyramineCholestyramine (With Sugar) | 14 | $2,330 |
| Lubiprostone | 14 | $2,001 |
| Pantoprazole Sodium | 197 | $1,975 |
| Omeprazole | 147 | $1,974 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 30 | $1,730 |
| PrevaliteCholestyramine | 11 | $1,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,421 | $54,27451 claims |
| GileadVemlidy | $210 | $17,99511 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $818 | $7,67915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Glendora
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.